Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

[The evaluation of chemotherapy for patients over eighty-years-old].

Sato K, Ito Y, Abe T, Akada T, Muto R, Nakanishi C, Dendo M, Ozawa Y, Sakashita K, Kato H.

Gan To Kagaku Ryoho. 2012 Apr;39(4):567-70. Japanese.

PMID:
22504679
2.

Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.

Kuriyama H, Kawana K, Taniguchi R, Jono F, Sakai E, Ohubo H, Suzuki H, Kobayashi S, Murata Y, Inamori M, Hata Y, Nahajima A.

Hepatogastroenterology. 2011 Mar-Apr;58(106):270-4.

PMID:
21661380
3.

Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.

Kuriyama H, Kawana K, Taniguchi R, Jono F, Sakai E, Okubo H, Suzuki H, Kobayashi S, Murata Y, Inamori M, Hata Y, Nakajima A.

Hepatogastroenterology. 2011 Jan-Feb;58(105):26-30.

PMID:
21510281
4.

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y.

J Immunother. 2011 Jan;34(1):92-9. doi: 10.1097/CJI.0b013e3181fb65b9.

PMID:
21150717
5.

Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.

Yukisawa S, Ishii H, Matsuyama M, Kuraoka K, Takano K, Kamei A, Ozaka M.

Jpn J Clin Oncol. 2011 Jan;41(1):76-80. doi: 10.1093/jjco/hyq160. Epub 2010 Oct 5.

PMID:
20926412
6.

Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.

Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T.

J Gastroenterol. 2010 Nov;45(11):1146-54. doi: 10.1007/s00535-010-0258-9. Epub 2010 Jun 15.

PMID:
20549255
7.

[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].

Moriwaki T, Hyodo I, Nishina T, Nasu J, Hidaka S, Kajiwara T, Tsuzuki T, Hirao K, Tsubouchi E, Yamauchi Y, Hirasaki S, Masumoto T, Tanada M.

Gan To Kagaku Ryoho. 2004 Sep;31(9):1373-6. Japanese.

PMID:
15446559
8.

Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.

Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH.

Jpn J Clin Oncol. 2005 Feb;35(2):68-73.

PMID:
15709089
9.

Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A.

Oncology. 2010;79(1-2):39-45. doi: 10.1159/000318020. Epub 2010 Nov 10.

PMID:
21063134
10.

Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.

Okubo S, Nishiuma S, Kobayashi N, Taketsuna M, Taniai H.

Jpn J Clin Oncol. 2012 Nov;42(11):1043-53. doi: 10.1093/jjco/hys149. Epub 2012 Oct 5.

PMID:
23042772
11.

Features of gemcitabine-related severe pulmonary toxicity: patients with pancreatic or biliary tract cancer.

Tamiya A, Endo M, Shukuya T, Igawa S, Tsuya A, Nakamura Y, Murakami H, Takahashi T, Boku N, Yamamoto N.

Pancreas. 2009 Oct;38(7):838-40. doi: 10.1097/MPA.0b013e3181ad97cf. No abstract available.

PMID:
19893461
12.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
13.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators..

N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.

14.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
15.

[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].

Gong JF, Zhang XD, Li J, Di LJ, Jin ML, Shen L.

Ai Zheng. 2007 Aug;26(8):890-4. Chinese.

PMID:
17697554
16.

[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].

Yajima T, Furukawa Y, Ishii Y, Hattori Y, Matsumoto N, Yamamoto M, Yamaoka Y, Fujihara M, Fujita M, Kuniki H.

Gan To Kagaku Ryoho. 2004 Jun;31(6):953-7. Japanese.

PMID:
15222120
17.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.

Milella M, Gelibter AJ, Pino MS, Bossone G, Marolla P, Sperduti I, Cognetti F.

Oncologist. 2010;15(2):e1-4. doi: 10.1634/theoncologist.2008-0135.

18.

[Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].

Sumii T, Funakoshi A, Ito T, Mizumoto K, Tanaka M, Migita Y, Sakai T, Shinozaki H, Yamaguchi H, Niyahara T, Muranaka T, Eriguchi N, Ueki T; Fukuoka Pancreatic Cancer Chemotherapy Group..

Gan To Kagaku Ryoho. 2003 Jul;30(7):971-6. Japanese.

PMID:
12894712
19.

[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].

Xie DR, Liang HL, Yang Q, Guo SS, Jiang ZM.

Ai Zheng. 2007 Aug;26(8):895-9. Chinese.

PMID:
17697555
20.

Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.

Park JK, Ryu JK, Lee JK, Yoon WJ, Lee SH, Kim YT, Yoon YB.

Pancreas. 2006 Nov;33(4):397-402.

PMID:
17079946

Supplemental Content

Support Center